TGF-β1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 371-381

  Liu, Shujuan ^a   Etto, Tamara ^a   Rodríguez Cruz, Tania ^a   Li, Yufeng ^a   Wu, Chenghan ^a   Fulbright, Orenthial J ^a   Hwu, Patrick ^a   Radvanyi, Laszlo ^a   Lizee, Gregory ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adoptive cell transfer; Immunotherapy; Melanoma; Tumor infiltrating lymphocyte tgf 1

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; MART1 ANTIGEN; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; HUMAN; HUMAN CELL; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; CELL SEPARATION; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; SECRETION;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85047698107     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cd1180     Document Type: Article

References (30)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
3. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-342.
4. Van Parijs L, Refaeli Y, Lord JD, et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fasmediated activation-induced cell death. Immunity. 1999;11:281-288.
5. Liu S, Riley J, Rosenberg S, et al. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J Immunother. 2006;29:284-293.
6. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factorbeta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
7. Das L, Levine AD. TGF-β inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction. J Immunol. 2008;180:1490-1498.
8. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163:1037-1050.
9. McKarns SC, Schwartz RH. Distinct effects of TGF-β 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol. 2005;174:2071-2083.
10. Inge TH, Hoover SK, Susskind BM, et al. Inhibition of tumorspecific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 1992;52:1386-1392.
11. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol. 2005;174:5215-5223.
12. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991-998.
13. Smyth MJ, Strobl SL, Young HA, et al. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol. 1991;146:3289-3297.
14. Xu H, Silver PB, Tarrant TK, et al. Tgf-b inhibits activation and uveitogenicity of primary but not of fully polarized retinal antigen-specific memory-effector T cells. Invest Ophthalmol Vis Sci. 2003;44:4805-4812.
15. Rich S, Seelig M, Lee HM, et al. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells. J Immunol. 1995;155:609-618.
16. Zhang X, Giangreco L, Broome HE, et al. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J Exp Med. 1995;182:699-709.
17. Sung JL, Lin JT, Gorham JD. CD28 co-stimulation regulates the effect of transforming growth factor-b1 on the proliferation of naive CD4+ T cells. Int Immunopharmacol. 2003;3:233-245.
18. Kim YJ, Stringfield TM, Chen Y, et al. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-b1 and 4-1BB costimulation. Blood. 2005;105:274-281.
19. Gunnlaugsdottir B, Maggadottir SM, Ludviksson BR. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-b1 on CD4+ and CD8+ naive human T-cells. Int Immunol. 2005;17:35-44.
20. Hsiao YW, Liao KW, Hung SW, et al. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-β1 and restores the lymphokine-activated killing activity. J Immunol. 2004;172:1508-1514.
21. Geller RL, Smyth MJ, Strobl SL, et al. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. J Immunol. 1991;146:3280-3288.
22. Cerwenka A, Kovar H, Majdic O, et al. Fas-and activationinduced apoptosis are reduced in human T cells preactivated in the presence of TGF-β1. J Immunol. 1996;156:459-464.
23. Rich S, Van Nood N, Lee HM. Role of α5 β1 integrin in TGF-β 1-costimulated CD8+ T-cell growth and apoptosis. J Immunol. 1996;157:2916-2923.
24. Genestier L, Kasibhatla S, Brunner T, et al. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med. 1999;189:231-239.
25. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
26. Marie JC, Letterio JJ, Gavin M, et al. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061-1067.
27. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-b. J Immunol. 2005;174:1446-1455.
28. Zheng SG, Wang J, Wang P, et al. IL-2 is essential for TGF-β to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178:2018-2027.
29. Zheng SG, Wang JH, Gray JD, et al. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol. 2004;172:5213-5221.
30. Wei J, Duramad O, Perng OA, et al. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104:18169-18174.